Application Note

Highly Efficient T Cell Manufacturing Process Using CellGenix® Reagents

Source: Sartorius

By Sarah Carqueville, Product Manager CellGenix GMP Media

CAR T-Cell Immunotherapy-GettyImages-1321031345

Cell and gene therapies, including T cell therapy, have become a promising approach for treating various diseases. However, the successful manufacturing of these therapies requires overcoming operational challenges associated with novel and emerging modalities. Specifically, the manufacturing process of T cell products, such as CAR T cells, must yield a sufficient number of cells with defined properties within a reasonable timeframe.

This study shows that enhanced T cell expansion as well as the generation of an early-differentiated phenotype can be achieved using CellGenix® reagents, a cell culture medium for T cells and cytokines, in a static bioreactor system, G-Rex®. Notably, these reagents are serum-free, and there is no need to add serum. This minimizes serum-associated risks and eliminates variability in the manufacturing process. Explore how T cell culture in CellGenix® GMP TCM effectively supports the expansion of CD8+ and CD4+ T cells within the G-Rex® bioreactor system.

access the Application Note!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Drug Discovery Online? Subscribe today.

Subscribe to Drug Discovery Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Drug Discovery Online